SXTC

Oct 22, 8:07 AMChina SXT Pharmaceuticals announces a 1-for-100 share consolidation of its Class A ordinary shares, effective at the open of trading on October 26, 2026.

Peers: UPC CPHI RGC ZYBT HKPD ZCMD WOK AHG ITOC ZJYL

Scroll to Statements

Index	-
Market Cap	0.37M
Enterprise Value	-26.69M
Income	-6.21M
Sales	1.14M
Book/sh	248057.71
Cash/sh	272.01
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	56
IPO	Jan 04, 2019

P/E	-
Forward P/E	-
PEG	-
P/S	0.32
P/B	0.00
P/C	0.01
P/FCF	-
EV/EBITDA	-
EV/Sales	-23.41
Quick Ratio	7.25
Current Ratio	7.93
Debt/Eq	0.04
LT Debt/Eq	0.02
Option/Short	No / Yes

EPS (ttm)	-64500.93
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	93.01% 84.85%
Sales past 3/5Y	-16.74% -24.94%
EPS Y/Y TTM	97.52%
Sales Y/Y TTM	-34.63%
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	15.00%
Insider Trans	0.00%
Inst Own	0.01%
Inst Trans	12.07%
ROA	-22.00%
ROE	-27.49%
ROIC	-20.41%
Gross Margin	21.85%
Oper. Margin	-630.63%
Profit Margin	-545.24%
SMA20	-96.16%
SMA50	-98.30%
SMA200	-99.98%
Trades

Shs Outstand	0.10M
Shs Float	0.09M
Short Float	0.75%
Short Ratio	0.00
Short Interest	0.00M
52W High	8375879.50 -100.00%
52W Low	3.81 -6.30%
Volatility	37.00% 53.49%
ATR (14)	78.79
RSI (14)	27.80
Beta	1.98
Rel Volume	2.05
Avg Volume	211.33K
Volume	40,685

Perf Week	-67.90%
Perf Month	-98.61%
Perf Quarter	-99.23%
Perf Half Y	-99.98%
Perf YTD	-100.00%
Perf Year	-100.00%
Perf 3Y	-100.00%
Perf 5Y	-100.00%
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	4.10
Price	3.57
Change %	-12.93%

Oct-22-26 08:00AM	China SXT Pharmaceuticals, Inc. Announces Share Consolidation (PR Newswire) -34.25%
Oct-21-26 08:00AM	China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right (PR Newswire) +11.79%
Oct-08-26 10:44AM	China SXT Pharmaceuticals Announces $12 Million Registered Direct Offering With Significant Dilution Potential (InvestorsHub) -87.86%
09:22AM	China SXT Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering (PR Newswire)
Aug-05-26 09:00AM	China SXT Pharmaceuticals, Inc. Announces Share Consolidation (GlobeNewswire) -45.57%
08:45AM	Loading…
Jul-23-26 08:45AM	China SXT Pharmaceuticals Inc. Announces $9 Million Registered Direct Offering (GlobeNewswire) -83.53%
Mar-23-26 09:00AM	China SXT Pharmaceuticals, Inc. Announces Share Re-classification (GlobeNewswire) +5.00%
Jan-30-26 09:00AM	China SXT Pharmaceuticals, Inc. Announces Share Consolidation (GlobeNewswire) -38.00%
Jan-15-26 09:00AM	CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC INITIATIVE TO APPLY AI TECHNOLOGY ACROSS THE TCM SUPPLY CHAIN (GlobeNewswire) +10.18%
Jan-09-26 02:50PM	China SXT Pharmaceuticals Inc. Announces $10 Million Registered Direct Offering (GlobeNewswire) -87.92%
Jan-08-26 09:20AM	CHINA SXT PHARMACEUTICALS, INC. ANNOUNCES STRATEGIC AI INSIGHTS INITIATIVE TO OPTIMIZE TRADITIONAL CHINESE MEDICINE PORTFOLIO, ENHANCE MARKET ANALYSIS AND EXPLORE AI-SUPPORTED CLINIC DEPLOYMENT (GlobeNewswire) -37.50%
Mar-17-25 08:30AM	China SXT Pharmaceuticals Has Regained Compliance with Nasdaq's Minimum Bid Price Deficiency (GlobeNewswire) -7.09%
Feb-21-25 12:35PM	China SXT Pharmaceuticals, Inc. Announces Share Consolidation (GlobeNewswire) -8.70%
Oct-07-24 04:15PM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (GlobeNewswire) -10.28%
Oct-26-23 04:05PM	China SXT Pharmaceuticals, Inc. Regained Compliance with Nasdaq's Minimum Bid Price Rule (GlobeNewswire) +6.75%
08:30AM	Loading…
Oct-04-23 08:30AM	China SXT Pharmaceuticals Announces One-for-Twenty-five Reverse Stock Split (GlobeNewswire)
Aug-02-23 06:03AM	China SXT Pharmaceuticals Full Year 2023 Earnings: US$0.89 loss per share (vs US$5.52 loss in FY 2022) (Simply Wall St.)
May-10-23 08:00AM	China SXT Pharmaceuticals, Inc. Receives 180-day Extension from Nasdaq to Meet Minimum Bid Price Rule (GlobeNewswire) +6.05%
Mar-29-23 09:43AM	Insiders who placed huge bets on China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) earlier this year would be disappointed with the 12% drop (Simply Wall St.)
Nov-07-22 08:00AM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (GlobeNewswire)
May-18-22 12:30PM	China SXT Pharmaceuticals, Inc. Announces 1 for 20 Reverse Share Split (GlobeNewswire) -27.93%
Mar-14-22 10:33PM	China SXT Pharmaceuticals, Inc. Enters into Securities Purchase Agreement to Issue a 6% Convertible Promissory Note in the Original Principal Amount of $2.8 Million (GlobeNewswire) -9.81%
Jan-20-22 12:30PM	Aegis Capital Corp. Acted as Sole Bookrunner on a $4.1 Million Underwritten Public Offering of Ordinary Shares, Inclusive of the Over-Allotment, for China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC). (ACCESSWIRE)
10:45AM	China SXT Pharmaceuticals, Inc. Announces Successful Closing of $4.1 Million Follow-on Underwritten Offering of Ordinary Shares and Pre-Funded Warrants With Simultaneous Exercise of the Over-Allotment (GlobeNewswire)
Jan-18-22 07:46AM	China SXT Pharmaceuticals Shares Plunge On $3.5M Equity Raise Issued At Steep Discount (Benzinga) -58.77%
06:47AM	China SXT Pharmaceuticals, Inc. Prices $3.5 Million Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares (GlobeNewswire)
Jan-14-22 05:43PM	China SXT Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Ordinary Shares and Pre-Funded Warrants to Purchase Ordinary Shares (GlobeNewswire)
02:00PM	China SXT Pharmaceuticals, Inc. Adds Newly Developed Kuihuapan and Zhudanfen Advanced TCMP Products, and Announces the Expected Continuous Growth of Its Production Capacity of Luxuejin (PR Newswire)
Dec-16-21 08:00AM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (PR Newswire)
Oct-18-21 08:00AM	China SXT Pharmaceuticals, Inc. Obtained a New Pharmaceutical Manufacturing Permit and Passed Its GMP Compliance-Inspection (PR Newswire) +9.59%
08:00AM	Loading…
Feb-19-21 08:00AM	China SXT Pharmaceuticals, Inc. Announces 1 for 4 Reverse Share Split (PR Newswire) -23.04%
Nov-26-20 08:16PM	Is China SXT Pharmaceuticals, Inc. (SXTC) A Good Stock To Buy? (Insider Monkey)
Sep-09-20 09:00AM	NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement (PR Newswire) +6.93%
May-29-20 03:08PM	Hedge Funds Warming Up To China SXT Pharmaceuticals, Inc. (SXTC) (Insider Monkey) -5.61%
Mar-16-20 09:00AM	China SXT Pharmaceuticals, Inc. Announces That It Received a Grant Supported by City Government (PR Newswire) -11.45%
Jan-28-20 09:35AM	How Does China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Compare To Its Industry, After Its Big Share Price Gain? (Simply Wall St.) -13.50%
Jan-24-20 02:23PM	China SXT Pharmaceuticals, Inc. Announces Plans to Increase Production (Business Wire)
Jan-16-20 08:00AM	China SXT Pharmaceuticals, Inc. Announced Regulatory Approval of Its DNA Exam Laboratory (PR Newswire) +6.98%
Jan-03-20 10:30AM	China SXT Pharmaceuticals, Inc. Received Nasdaq Notification Letter Regarding Bid Price Deficiency (PR Newswire)
Dec-04-19 07:10AM	What Is China SXT Pharmaceuticals's (NASDAQ:SXTC) P/E Ratio After Its Share Price Tanked? (Simply Wall St.)
Nov-14-19 11:30AM	Should You Worry About China SXT Pharmaceuticals, Inc.s (NASDAQ:SXTC) ROCE? (Simply Wall St.)
Sep-11-19 07:00AM	China SXT Pharmaceuticals, Inc. Granted to Establish Taizhou Research Center for Advanced TCMP Engineering Techniques (PR Newswire)
Aug-19-19 08:00AM	China SXT Pharmaceuticals, Inc. Announces Filing of Annual Report on Form 20-F for Year Ended March 31, 2019 (PR Newswire)
Aug-12-19 08:00AM	China SXT Pharmaceuticals, Inc. Receives New Pharmaceutical GMP Certificate (PR Newswire) +20.26%
Jul-03-19 08:00AM	China SXT Pharmaceuticals, Inc. Announces TCM Homologous Supplements Production (PR Newswire)
May-22-19 11:20AM	China SXT Pharmaceuticals, Inc. Being Admitted to Hi-tech Zone of Huangshan City in Anhui Province (PR Newswire)
Apr-17-19 09:00AM	China SXT Pharmaceuticals, Inc. Announces Pricing of a $15 Million PIPE Financing (PR Newswire) -11.72%
Apr-02-19 06:30AM	China SXT Pharmaceuticals, Inc. Receives National High-tech Enterprise Qualification (PR Newswire)
Mar-28-19 06:30AM	China SXT Pharmaceuticals, Inc. Announces Financial Results for the Six Months Ended September 30, 2018 (PR Newswire)
Jan-30-19 02:25PM	4 Healthcare Stocks Looking To Finish Strong On Wednesday (1/30/19) (ACCESSWIRE) +43.81%
Jan-04-19 07:30AM	China SXT Pharmaceuticals, Inc. Announces Final Closing of Initial Public Offering (PR Newswire)

Show Previous News

China Sxt Pharmaceuticals, Inc. operates as a holding company, which engages in the research, development, manufacture, marketing, and sales of traditional Chinese medicine pieces (TCMP). Its product categories include directly-oral, after-soaking-oral, fine, and regular TCMP. The firm distributes its product under the Suxuantang brand. The company was founded by Feng Zhou in 2005 and is headquartered in Taizhou, China.

Chairman of the Board & Co-CEOMr. Feng Zhou

Co-Chief Executive OfficerMr. Sze Beng Lim

Chief Financial OfficerMr. Xiaodong Pan

Executive DirectorMr. Jun Zheng

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

China SXT Pharmaceuticals Inc

Upgrade your Finviz experience